Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
Yukai Huang, Wei‐Chung Cheng, Ting-Ting Kuo, Juan‐Cheng Yang, Yang‐Chang Wu, Heng‐Hsiung Wu, Chia-Chien Lo, Chih-Ying Hsieh, Sze-Ching Wong, Chih‐Hao Lu, Wan-Ling Wu, Shih‐Jen Liu, Yi‐Chuan Li, Ching‐Chan Lin, Chia‐Ning Shen, Mien‐Chie Hung, Jaw‐Town Lin, Chun‐Chieh Yeh, Yuh‐Pyng Sher
Topics & Concepts
KRASCancer researchPancreatic cancerGemcitabineDisintegrinBiologyAutophagyContext (archaeology)CancerInternal medicineMedicineMetalloproteinaseMatrix metalloproteinaseApoptosisGeneticsColorectal cancerPaleontologySignaling Pathways in DiseasePeptidase Inhibition and AnalysisProtease and Inhibitor Mechanisms